Skip to main content Skip to navigation

Dr Michael Khan



Senior Lecturer (Clinical)


Life Sciences
University of Warwick
Tel: 76528975

Research Interests

RNAi Tissue plasticity Cancer Biology Lipid metabolism Diabetes Head of Molecular Medicine @ Warwick and Director of Postgraduate Course in Cardiovascular risk and Organiser of MSc modules in CV risk


Executive Director Silence Therapeutics PLC 2013-present, CMO from 2012-2014, Head of Translational Medicine 2015-present: 3 years of board-level experience in Industry. Head hunted to join this RNAi therapeutics company, initially as an NED and advisor in 2012 and invited to become CMO and Executive Director later that year. Formulated company strategy for R and D, planning and initiating preclinical and translational projects. Managing relationships with CROs and academic collaborators. Active across many thematic areas of drug development from preclinical through regulatory and planning, initiation and running of Clinical Trials. Contributed to three successful fund-raising efforts and took part in all road-shows/funder presentations, raising over £80,000,000 since 2013. Invited speaker at several industry events/conferences. Have been the public face of the company at conferences. Over 30 years of clinical experience, including 17 years as a senior NHS consultant physician and clinical academic, in general medicine, diabetes and endocrinology: Run county coronary prevention and diabetes clinical services. General medical take and in-patient care. Strong track record in service development, research and high-level senior management both in the NHS and University. Have held numerous senior roles at national and international level, including with the EC and NICE. Much of this past expertise and experience is directly relevant to translational research, decision making and strategic planning in industry. Given, the emphasis on partnerships between academia and industry now in drug development, my experience of both sectors at high-level will be very useful. Maintained Clinical and research position at 1 day a week. This was deemed to be advantageous for Silence Therapeutics PLC and was accepted by UHCW and University of Warwick for the same reasons, namely helping to build academic-private sector partnerships. Has facilitated development of new clinical trials in HNSCC, a preclinical programme in preeclampsia and a drug delivery programme for ODN using conjugation chemistry. Other Relevant experience Expert advisor to NICE. Expert advisor and panel member Clinical Guidelines Development Group (CGDG) and NICE for Cardiovascular risk and lipid-lowering drugs 2012-2014. Made a substantial contribution, over 2 years, to developing and writing the new NICE guideline (CG181) on Lipid-lowering drugs and assessment of cardiovascular risk. Overall extended access to statins to over 5 million more adults in England by reducing the risk threshold for intervention from 20% to a 10% predicted risk of CVD over 10 years. Highly cited researcher, over 100 publications across basic science and clinical medicine including in Cell, Nature, BMJ and Lancet. Just under 3000 citations, H-factor 18. Published the second edition of the popular Molecular Biology of Cancer- Willey-Blackwell. Grants and awards, 2 active grants and over 2 million pounds funding from BBSRC and QNRF, looking at pregnancy-associated diabetes and colon cancer biomarkers respectively. Elected to FRCS and Association of Physicians. EC advisor. 2002- present. Senior administrative roles. Head of Molecular Medicine at University of Warwick from 2002-2006 (completed 5 year period). Member of Senior Management group for Department of Biological Sciences, 2002-2006. One of the pioneers of Warwick Systems Biology. Chair of the exam boards for Cardiovascular risk and Cancer biology MSc courses and Postgraduate awards. 2010- 2015: Member of the trust resuscitation committee and am senior member on the local ethics committee. Founder member and board for MLSRF charity (Chair- Sir Paul Nurse). Founder member and advisory board for the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM). In 2011 and 2014, Organiser, scientific committee member and local host for HEART UK. Grant reviewer and research analyst Extensive experience reviewing large multi-million euro grants for the EC; Marie Curie, ITNs, STREPS, NoEs, IPs, from FP5 through to Horizon 2020. Also for the BBSRC, EPSRC and MRC in the UK. Also grants aimed specifically at private sector funding, including Eurostars. Experience in applying for Innovate UK grants. Acted as advisor on infrastructure funding to the Government of Cyprus on behalf of the EC. Frequent reviewer for scientific journals.

Research Projects

View Current Projects        View All Projects


View All Publications

Update your user profile on Ideate


Research Themes:

Biomedical Science